Agentless security for untouchable IoT devices

Tern plc

The rapid expansion of connected devices across enterprise and industrial environments presents a pressing security challenge for organisations preparing for 2026 and beyond. Increasingly, a large portion of a company’s device estate cannot be secured through traditional software agents or conventional update mechanisms. Many sensors, embedded controllers, medical instruments and legacy systems are either incapable of running additional software, cannot tolerate downtime for patching, or are geographically dispersed in remote or hostile environments.

Conventional endpoint security, built on the assumption that every device can host a monitoring agent, struggles at scale in environments where devices are resource constrained or run proprietary firmware. Attempting to retrofit traditional security tools often results in blind spots across thousands of device types from hundreds of vendors, increasing attack surface and operational complexity.

Agentless IoT security reframes this problem by decoupling protection from the devices themselves. Instead of installing security software on each endpoint, agentless solutions observe devices from the outside. They use network traffic analysis, infrastructure logs and application interfaces to discover and classify every IP‑connected device. By doing so, organisations gain visibility into assets they did not even know existed. This inventory of devices and behaviours becomes the foundation for identity‑based controls and policy enforcement that can be applied without touching the device itself.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search